Alternative tumor markers in the diagnosis of ovarian cancer

Burcu Kısa Karakaya; Eralp Başer; Berk Bildacı; Esra Çabuk Cömert; Nilufer Bayraktar; Polat Dursun; Esra Kuşçu; Ali Ayhan

doi:10.5603/GP.2016.0045

Vol 87, No 8 (2016)

Research paper

Published online: 2016-08-31

View PDF

Download PDF file

View HTML

Get Citation

Alternative tumor markers in the diagnosis of ovarian cancer

Burcu Kısa Karakaya, Eralp Başer, Berk Bildacı, Esra Çabuk Cömert, Nilufer Bayraktar, Polat Dursun, Esra Kuşçu, Ali Ayhan

DOI: 10.5603/GP.2016.0045

Pubmed: 27629130

Ginekol Pol 2016;87(8):565-769.

Vol 87, No 8 (2016)

ORIGINAL PAPERS Gynecology

Published online: 2016-08-31

Abstract

Objectives: The aim of the study was to assess the usefulness of various tumor markers (CA125, HE4, bcl2) measured in serum, urine and saliva in the differential diagnosis of adnexal masses.

Material and methods: Our study was conducted at the Başkent University Medical School, Department of Obstetrics and Gynecology, Ankara, Turkey, between November 2010 and March 2011. Fifty patients with a suspicion of malignant adnexal mass and 30 controls were included in the study. Serum and urine CA-125, HE4, and bcl2 levels were evaluated for their role in the diagnosis of epithelial ovarian cancer (EOC).

Results: Serum CA-125 and HE4 levels, and urine HE4 levels were significantly higher in malignant cases as compared to controls (p < 0.05). Mean levels of bcl2 in saliva and urine were similar in malignant cases and controls (p > 0.05).

Conclusions: We demonstrated that serum CA125, serum HE4 and urine HE4 levels were elevated in patients with ovarian cancer. These findings should be assessed in future studies with larger sample sizes in order to reach more definite conclusions.

Abstract

Objectives: The aim of the study was to assess the usefulness of various tumor markers (CA125, HE4, bcl2) measured in serum, urine and saliva in the differential diagnosis of adnexal masses.